A competing risk-based nomogram to predict cancer-specific survival in patients with retroperitoneal leiomyosarcoma

Figures

• 

  Fig. 1. Flowchart of the inclusion and exclusion process.

• 

  Fig. 2. Nomogram to predict 1-, 3- and 5-year cancer-specific survival in patients with RLMS (A). Receiver-operating characteristic curves (ROCs) and area under the curves (AUCs) of the nomogram and the AJCC 8th Staging system for predicting cancer-specific survival at 1-, 3-, and 5-year in training (B) and validation (C) cohorts respectively. Calibration plots at 1-, 3-, and 5- year (D) in the training cohort and 1-, 3-, and 5- year (E) in the validation cohort.

• 

  Fig. 3. Decision curve analysis for (A) 1-year net benefit in training cohort; (B) 3-year net benefit in training cohort; (C) 5-year net benefit in training cohort; (D) 1-year net benefit in validation cohort; (E) 3-year net benefit in validation cohort; (F) 5-year net benefit in validation cohort.

• 

  Fig. 4. Kaplan–Meier cancer-specific survival analysis of RLMS patients in low, middle, and high-risk groups according to the nomogram score in the training (A) and validation (B) cohorts. Kaplan–Meier cancer-specific survival analysis of RLMS patients stratified by the AJCC 8th Staging system in the training (C) and validation (D) cohorts.